Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius Medical Care AG & Co. KGaA

Investor Presentation • Sep 17, 2010

165_ip_2010-09-17_e212f45e-225b-4618-a575-8654e414600b.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Fresenius Medical Care

The World's Leading Renal Therapy Company

Bank of America Merrill Lynch Global Healthcare Conference 2010 September 17, 2010

Safe Harbor Statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

2. Financials and Outlook

3. Growth Strategy and Summary

Strong quarter and fully on track for full-year targets

Very good underlying performance

Q
2
2
0
0
9		 Q
2
2
0
1
0		 G
h
t
r
o
w
R
e
e
n
e
v
u		 \$
2
7
6
4
m
,		 \$
2
9
4
6
m
,		 %
7
N
i
t
e
n
c
o
m
e
i
bu
b
le
F
M
C
A
G
&
Co
K
Ga
A
t
tr
ta
to
a		 \$
2
2
1
m		 \$
2
4
8
m		 1
2
%
E
i
h
a
r
n
n
g
s
p
e
r
s
a
r
e		 \$
0
4
7		 \$
0
8
3		 1
2
%
  • •Strong revenue growth at 7% at constant currency and 6% organic
  • •Excellent EBIT-margin development
  • •Resulting in very good net income growth

Total revenue increased 9% to \$5,828 m

© 2010 Fresenius Medical Care AG & Co. KGaA

Very strong revenue growth globally

\$
U
S
i
l
l
i
m
o
n
s		 H
1
2
0
0
9		 H
1
2
0
1
0		 G
h
t
r
o
w		 c
c
N
h
A
i
t
o
r
m
e
r
c
a		 3
2
5
4
,		 3
5
8
7
,		 1
0
%
I
i
l
t
t
n
e
r
n
a
o
n
a		 7
2
3		 8
1
7		 1
3
%		 9
%
T
l
t
o
a		 3
9
7
7
,		 5
4
3
9
,		 1
1
%		 1
0
%
  • •Good organic treatment growth of 4.3% globally
  • •Continued strong revenue per treatment development

cc = constant currency

2nd Quarter 2010 – Revenue per treatment US

Good product growth in H1 2010

\$
U
S
i
l
l
i
m
o
n
s		 H
1
2
0
0
9		 H
1
2
0
1
0		 G
h
t
r
o
w		 c
c
T
l
t
o
a
r
e
e
n
e
v
u
(
)
inc
l.
in
l r
te
rn
a
ev
en
ue		 1
8
1
3
,		 1
9
6
2
,		 8
%		 6
%
E
l
t
e
r
n
a
r
e
e
n
e
x
v
u		 1
3
4
6
,		 1
4
3
3
,		 6
%		 4
%
N
h
A
i
t
o
r
m
e
r
c
a		 3
9
6		 4
0
8		 3
%
I
i
l
t
t
n
e
r
n
a
o
n
a		 9
5
0		 5
1
0
2
,		 8
%		 4
%

cc = constant currency

Expanded Dialysis Services and Products in Key Regions

  • X Acquired Asia Renal Care
  • XAdding more than 100 clinics treating about 6,200 patients
  • XAdding approximately \$80 million in annual revenue
  • X Expanded dialysis products business in Korea
  • XAdding approximately \$15 million in annual revenue
  • XAccretive to earnings in the first year
  • X Entered into long-term distributor agreement in Japan

Asia

Pacific

  • X Expanded dialysis services business in Russia
  • XAdding approximately \$25 million in annual revenue

  • XAccretive to earnings in the first year

  • Business Update

2. Financials and Outlook

  1. Growth Strategy and Summary
\$
S
U
i
l
l
i
m
o
n
s		 H
1
2
0
0
9		 H
1
2
0
1
0		 G
h
t
r
o
w
N
t
e
r
e
e
n
e
v
u		 3
2
3
5
,		 5
8
2
8
,		 *
9
%
O
(
)
i
i
E
B
I
T
t
p
e
r
a
n
g
n
c
o
m
e		 8
1
3		 8
8
8		 9
%
E
B
I
T
i
i
%
m
a
r
g
n
n		 1
5
3		 1
5
2
I
t
t
t
n
e
r
e
s
e
x
p
e
n
s
e
n
e
,		 1
4
9		 1
3
5
I
b
f
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 6
6
4		 5
3
7		 1
3
%
I
t
n
c
o
m
e
a
e
p
e
n
s
e
x
x		 2
1
4		 2
5
7
T
t
a
r
a
e
x		 3
2
%		 3
4
%
N
l
l
i
i
t
t
t
o
n
-c
o
n
r
o
n
g
n
e
r
e
s		 3
1		 3
7
N
i
t
e
n
c
o
m
e
i
bu
b
le
F
M
C
A
G
&
Co
K
Ga
A
t
tr
ta
to
a		 4
1
9		 4
5
9		 1
0
%

* 8% growth at constant currency, 7% organic growth

Continued excellent cash collection

Operating cash flow at 11% of revenue

\$
U
S
i
l
l
i
m
o
n
s		 H
1
2
0
0
9		 H
1
2
0
1
0		 G
h
t
r
o
w
1)
O
f
i
h
l
t
p
e
r
a
n
g
c
a
s
o
w		 4
3
7		 6
4
3
1
1
%
f r
o
ev
e
nu
e		 4
%
7
1)
C
i
l
d
i
t
t
a
p
a
e
x
p
e
n
u
r
e
s
t
n
e
,		 (
)
2
4
9		 (
)
2
1
8
f
F
h
l
r
e
e
c
a
s
o
w		 1
8
8		 4
2
5
f r
7
%
o
ev
e
nu
e		 1
2
7
%
1)
2)
A
i
i
i
t
f
c
q
s
o
n
s
d
i
i
u
t
t
t
n
e
o
e
s
r
e
s
v
u
,		 (
)
8
1		 (
)
1
5
0
1)
2)
F
h
f
l
f
i
i
i
r
e
e
c
a
s
o
w
t
t
a
e
r
a
c
q
u
s
o
n
s
,		 1
0
7		 2
5
7

1) A reconciliation to the most directly comparable U.S. GAAP financial measure is provided in the attachment.

2) Does not include a \$133 m cash out for a short-term bank deposit in Q2 2010 and a cash repayment in form of an inter-company loan of \$ 50 m in Q2 2009

2010 – Outlook Reiterated

Fully on track for 2010 Targets

\$
S
U
i
l
l
i
m
o
n
s		 C
G
U
I
D
A
N
E
N
t
e
r
e
e
n
e
v
u		 \$
1
2
0
0
0
>
,
N
i
t
e
n
c
o
m
e
i
bu
b
le
F
M
C
A
G
&
Co
K
Ga
A
t
tr
ta
to
a		 \$
9
5
0
9
8
0
-
L
i
t
e
v
e
r
a
g
e
r
a
o
(
D
b
/
E
B
I
T
D
A
)
t
e		 2
5
<
C
i
l
d
i
t
t
a
p
a
e
x
p
e
n
u
r
e
s		 \$
0
6
0
5
5
5
~
-
A
i
i
i
t
c
q
s
o
n
s
u		 \$
0
0
5
t
u
p
o

  1. Business Update

  2. Financials and Outlook

3. Growth Strategy and Summary

Global prevalence increased by 80% over the last 10 years

© 2010 Fresenius Medical Care AG & Co. KGaA

Development of Dialysis Patient Numbers

  • Renal failure persists worldwide
  • Dialysis is the primary treatment modality on a global scale
  • The number of global dialysis patients is expected to double by 2020

Continued Growth Opportunities

i
2
0
1
0
G
d
u
a
n
c
e
-		 G
l
1
3
o
a
R
e
e
n
e
s
v
u		 \$
1
2
b
n
>		 6
8
%
G
h
*
t
r
o
w
-
i
E
B
I
T
M
a
r
g
n
s		 5
1
6
%
~		 1
0
2
0
b
p
s
-
(
i
l
i
)
t
n
c
r
e
m
e
n
a
n
c
r
e
a
s
e
s
p
a.
I
E
t
t
n
e
r
e
s
p
e
n
s
e
x		 5
5
%
<		 5
6
0
6
%
t
o
T
R
t
a
x
a
e		 3
4
5
3
5
5
%
–		 5
3
3
6
%
–
N
I
t
e
n
c
o
m
e
C
G
Co
Ga
i
bu
b
le
F
M
A
&
K
A
t
tr
ta
to
a		 \$
9
5
0
9
8
0
-		 H
i
h
i
l
t
g
s
n
g
e
o
l
d
b
l
d
i
i
t
o
o
e
g
s
w
u
C
O
i
h
F
l
t		 f
1
0
%
R		 1
0
%
f
R
p
e
r
a
n
g
a
s
o
w		 o
e
e
n
e
v
u
>		 o
e
v
e
n
u
e
>
C
E
A
i
i
i
t
a
p
c
q
s
o
n
s
x
u
+		 f
9
%
R
o
e
e
n
e
v
u
~		 %
f
R
7
o
e
e
n
e
v
u
~
L
d
h
i
e
a
e
r
s
p		 M
i
i
l
b
l
l
d
h
i
i
i
t
t
a
n
a
n
o
u
r
g
o
a
e
a
e
r
s
p
p
o
s
o
n
•
C
f
f
i
h
h
h
d
i
l
i
i
d
t
t
t
t
t
t
o
n
n
e
o
s
a
p
e
e
r
e
o
e
a
s
s
n
s
r
u
u
u
y
u
y
•
Q
i
l
t
a
u
y		 M
i
i
i
l
i
i
d
d
i
t
t
t
a
n
a
n
s
u
p
e
r
o
r
q
u
a
y
n
p
r
o
u
c
s
a
n
s
e
r
v
c
e
s
•
G
h
t
r
o
w		 f
i
f
i
i
B
d
t
t
t
e
n
e
r
o
m
p
r
o
c
n
n
o
a
o
n
s
•
u
v
i
f
i
i
i
T
k
l
h
l
t
t
t
t
t
t
t
a
e
o
p
p
o
r
n
o
n
e
r
n
a
o
n
a
g
r
o
p
o
e
n
a
•
u
y
w
I
d
h
f
f
i
t
t
n
r
o
c
e
n
e
e
r
a
p
o
e
r
n
g
s
•
u
w
y
C
i
h
i
l
i
f
i
d
d
t
t
t
o
n
n
u
e
o
r
z
o
n
a
e
x
p
a
n
s
o
n
o
s
e
r
v
c
e
a
n
p
r
o
u
c
r
a
n
g
e
•
F
i
i
l
n
a
n
c
a		 C
l
d
d
i
t
t
o
n
r
o
c
o
s
a
n
s
p
e
n
n
g
•
S
k
i
i
i
i
t
t
t
t
t
t
t
e
e
a
r
a
c
v
e
n
v
e
s
m
e
n
o
p
p
o
r
u
n
e
s
•
C
i
f
i
b
l
h
t
t
t
t
o
n
n
e
p
r
o
a
e
g
r
o
m
o
m
e
n
m
u
w
u
•

Thank you for your interest in Fresenius Medical Care !

Fresenius Medical Care

The World's Leading Renal Therapy Company

Bank of America Merrill Lynch Global Healthcare Conference 2010 September 17, 2010

Reconciliation of non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measure

All figures are in \$ millions

D
b
t
e		 Q
2
2
0
1
0		 F
Y
2
0
0
9		 F
Y
2
0
0
8		 F
Y
2
0
0
7
S
in
(
in
/
)
ho
t-
te
bo
l.
A
R
r
rm
rro
w
g
s
c
p
ro
g
ra
m		 4
1
0		 3
1
6		 6
8
4		 2
1
7
S
fro
ho
bo
ing
la
d
ies
t-
te
te
t
+
r
rm
rro
w
s
m
re
p
ar		 9 1
0		 1 2
Cu
f
t p
t
ion
lon
te
de
b
t a
d
i
ta
l
lea
b
l
ig
t
ion
+
rre
n
or
o
g-
rm
n
ca
p
se
o
a
s		 1,
8
6
6		 1
5
8		 4
5
5		 8
5
Cu
ion
f
fe
d
i
ies
t p
t
tru
t p
t
+
rre
n
or
o
s
re
rre
se
cu
r		 6
0
7
Lo
de
b
d
i
l
lea
b
l
ig
ion
-te
t a
ta
t
+
ng
rm
n
ca
p
se
o
a
s,
les
t p
t
ion
s c
ur
re
n
or		 2,
9
4
9		 4,
4
2
8		 3,
9
5
7		 4,
0
0
4
Tr
fe
d
i
ies
t p
t
+
us
re
rre
se
cu
r		 5
9
3		 6
5
6		 6
4
1		 6
6
4
To
l
de
b
ta
t
=		 5,
8
2
7		 5,
5
6
8		 5,
7
3
8		 5,
6
4
2
E
B
I
T
D
A		 Q
2
2
0
1
0		 F
Y
2
0
0
9		 1
)
F
Y
2
0
0
8		 F
Y
2
0
0
7
La
lve
hs
in
in
(
E
B
I
T
)
t
tw
t
t
s
e
m
on
o
p
er
a
g
co
m
e		 1,
8
3
0		 1,
7
5
6		 1,
6
7
2		 1,
5
8
0
La
lve
hs
de
ia
ion
d
iza
ion
t
tw
t
t
t
t
+
s
e
m
on
p
re
c
a
n
am
or		 4
8
7		 4
5
7		 4
1
6		 3
6
3
No
h
ha
+
n-
ca
s
c
rg
es		 4
9		 5
0		 4
4		 4
1
(
ize
)
E
B
I
T
D
A
l
d
an
nu
a
=		 2,
3
6
6		 2,
2
6
3		 2,
1
3
2		 1,
9
8
4
C
i
l
d
i
(
)
t
t
t
a
p
a
e
p
e
n
r
e
n
e
x
u		 H
1
2
0
1
0		 H
1
2
0
0
9		 Q
2
2
0
1
0		 Q
2
2
0
0
9
Pu
ha
f p
la
d
ip
ty
t
t
rc
s
e
o
ro
p
e
r
p
n
a
n
e
q
m
e
n
u
,		 (
)
2
2
7		 (
)
2
5
4		 (
)
1
2
1		 (
)
1
4
2
Pr
d
fro
le
f p
la
d
ip
ty
t
t
o
c
e
e
s
m
s
a
o
ro
p
e
r
p
n
a
n
e
q
m
e
n
u
-
,		 9 5 2 3
C
i
l
d
i
(
)
t
tu
t
a
p
a
e
x
p
e
n
r
e
n
e
=		 (
)
2
1
8		 (
)
2
4
9		 (
)
1
1
9		 (
)
1
3
9

1) Excluding restructuring costs and in-process R&D

Reconciliation of non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measure

E
l
R
t
x
e
r
n
a
e
v
e
n
u
e		 H
1
2
0
1
0		 H
1
2
0
0
9		 G
h
t
ro
w		 cc Q
2
2
0
1
0		 Q
2
2
0
0
9		 G
h
t
ro
w		 cc
I
i
l
du
t
t
t
n
e
r
n
a
o
n
a
p
ro
c
re
ve
nu
e		 1,
2
0
7		 1,
1
0
9		 9 5 6
0
4		 5
9
5		 1 2
In
l r
t
e
rn
a
ev
e
nu
e
-		 (
)
1
8
2		 (
)
1
5
9		 1
5		 (
)
9
2		 (
)
8
5		 8
Ex
t
l
e
r
n
a
r
e
v
e
nu
e
=		 1,
0
2
5		 9
5
0		 8 4 5
1
2		 5
1
0		 0 2
N
h
A
i
du
t
t
o
r
m
e
r
c
a
p
ro
c
re
ve
nu
e		 7
5
5		 7
0
4		 7 3
9
0		 3
6
0		 8
In
l r
t
e
rn
a
ev
e
nu
e
-		 (
)
3
4
7		 (
)
3
0
8		 1
2		 (
)
1
8
0		 (
)
1
6
1		 1
2
Ex
l
t
e
r
n
a
r
e
v
e
nu
e
=		 4
0
8		 3
9
6		 3 2
1
0		 1
9
9		 5
T
O
T
A
L
du
t
p
ro
c
re
ve
nu
e		 1,
9
6
2		 1,
8
1
3		 8 6 9
9
4		 9
5
5		 4 5
In
l r
t
e
rn
a
ev
e
nu
e
-		 (
)
5
2
9		 (
)
4
6
7		 1
3		 (
)
2
7
2		 (
)
2
4
6		 1
1
Ex
l
t
e
r
n
a
r
e
v
e
nu
e
=		 1,
4
3
3		 1,
3
4
6		 6 4 7
2
2		 7
0
9		 2 3

All figures are in \$ millions

(
)
A
i
i
i
t
t
c
q
u
s
o
n
s
n
e		 H
1
2
0
1
0		 H
1
2
0
0
9		 Q
2
2
0
1
0		 Q
2
2
0
0
9
Ac
is
i
io
d
in
d
ha
f
in
i
b
le
t
t
t
t
t
t
q
u
ns
a
n
ve
s
m
e
n
a
n
ne
p
u
rc
s
e
s
o
a
ng
a
s
s
e
s		 (
2
9
1
)		 (
8
2
)		 (
2
0
)
7		 (
4
)
5
Pr
d
fro
d
ive
i
t
tu
o
c
e
e
s
m
s
re
s		 8 5
1		 6 5
0
f
Ac
is
i
io
d
in
d
ive
i
t
t
t
t
t
tu
q
ns
a
n
ve
s
m
e
n
s,
n
e
o
s
re
s
u		 (
)
2
8
3		 (
)
3
1		 (
)
2
0
1		 5
In
f r
t
t,
t
t
ve
s
m
e
n
ne
o
e
p
ay
m
e
n
s		 1
3
3		 (
)
5
0		 (
)
1
3
3		 (
)
5
0
Ac
is
i
io
f
d
ive
i
t
t
t
tu
q
u
ns
ne
o
s
re
s
,		 (
)
1
5
0		 (
)
8
1		 (
)
6
8		 (
)
4
5

cc = constant currency

Global Presence Products & Services

© 2010 Fresenius Medical Care AG & Co. KGaA

Dialysis Services Worldwide – Number of Patients Treated 2009*

* Based on company statements and estimates

* 13,606 patients including managed clinics

*

Market Position Globally

1,895,000 Dialysis Patients in 2009

Dialysis patients treated in 2009 by company

Market Position by Major Product Groups

R
k
1
a
n		 R
k
2
a
n		 R
k
3
a
n
D
i
l
a
y
z
e
r
s		 F
M
E		 G
b
a
m
r
o		 i
N
p
r
o
i
i
i
D
l
h
a
s
s
m
a
c
n
e
s
y		 F
M
E		 G
b
a
m
r
o		 N
i
k
k
i
s
o
H
d
i
l
i
t
t
e
m
o
a
y
s
s
c
o
n
c
e
n
r
a
e
s		 F
M
E		 F
u
s
o		 G
b
a
m
r
o
i
B
l
d
l
o
o
n
e
s		 F
M
E		 G
b
a
m
r
o		 K
i
a
a
s
m
w
u
P
i
l
d
i
l
i
d
t
t
e
r
o
n
e
a
a
y
s
s
p
r
o
u
c
s		 B
t
a
x
e
r		 F
M
E		 i
P
s
a

Produced more than ~85,000,000 Dialyzers in 2009

Q
2
2
0
1
0		 C
i
i
l
n
c
s		 i
P
t
t
a
e
n
s		 T
t
t
r
e
a
m
e
n
s
(
in
i
l
l
io
)
m
ns
T
l
t
o
a		 2
9
9
5
,		 2
0
2
4
1
4
,		 1
3
5
G
h
t
r
o
w		 %
5
+		 6
%
+		 6
%
+
N
h
A
i
t
o
r
m
e
r
c
a		 1
9
7
5
,		 1
3
0
8
8
5
,		 1
0
2
G
h
t
r
o
w		 4
%
+		 5
%
+		 6
%
+
I
i
l
t
t
n
e
r
n
a
o
n
a		 8
0
4		 6
7
3
2
6
,		 5
0
G
h
t
r
o
w		 9
%
+		 1
1
%
+		 8
%
+
E
r
o
p
e
u		 4
6
3		 3
5
2
7
7
,		 2
6
L
i
A
i
t
a
n
m
e
r
c
a		 1
9
3		 2
1
6
1
7
,		 1
7
A
i
P
i
f
i
s
a
a
c
c
-		 1
4
8		 1
0
2
8
8
,		 0
8
H
1
2
0
0
9		 H
1
2
0
1
0		 G
h
t
r
o
w
R
e
v
e
n
u
e		 \$
5
3
2
3
m
,		 \$
5
8
2
8
m
,		 9
%
+
i
N
t
e
n
c
o
m
e
i
bu
b
le
F
M
C
A
G
&
Co
K
Ga
A
t
tr
ta
to
a		 \$
4
1
9
m		 \$
4
5
9
m		 1
0
%
+
E
i
h
a
r
n
n
g
s
p
e
r
s
a
r
e		 \$
1
4
1		 \$
1
5
3		 9
%
+
  • •Strong revenue growth at 8% at constant currency and 7% organic
  • •Continued excellent cash flow development

cc = constant currency

Very strong revenue growth globally

First time over 200,000 patients being treated

\$
S
U
i
l
l
i
m
o
n
s		 Q
2
2
0
0
9		 Q
2
2
0
1
0		 G
h
t
r
o
w		 c
c
i
N
h
A
t
o
r
m
e
r
c
a		 1
6
7
7
,		 1
8
1
7
,		 8
%
i
I
l
t
t
n
e
r
n
a
o
n
a		 3
7
7		 4
0
7		 8
%		 9
%
T
l
t
o
a		 2
0
5
4
,		 2
2
2
4
,		 8
%		 8
%
  • •Good organic treatment growth of 4.3% globally
  • •Continued strong revenue per treatment development
  • •Treating 202,414 patients in 2,599 clinics

cc = constant currency

© 2010 Fresenius Medical Care AG & Co. KGaA

Very good performance in all key metrics

Q
2
2
0
1
0		 T
l
t
o
a		 N
h
A
i
t
o
r
m
e
r
c
a		 I
i
l
t
t
n
e
r
n
a
o
n
a
O
i
h
t
r
g
a
n
c
r
e
e
n
e
g
r
o
v
u
w		 7
%		 7
%		 5
%
S
k
h
t
t
t
t
t
a
m
e
m
a
r
e
r
e
a
m
e
n
g
r
o
w		 4
3
%		 4
2
%		 4
4
%
R
t
t
t
e
e
n
e
p
e
r
r
e
a
m
e
n
v
u		 1
)
\$
3
4
9		 \$
1
9
5
J
3
0
2
0
1
0
n
e
u
,
N
b
f
l
i
i
m
e
r
o
c
n
c
s
u		 2
5
9
9
,		 1
7
9
5
,		 8
0
4
G
h
t
r
o
w		 %
5		 4
%		 9
%
D
e
n
o
o
s
v		 4
5		 2
8		 1
7

1) including Mexico

cc = constant currency

© 2010 Fresenius Medical Care AG & Co. KGaA

Good product growth in North America

\$
S
U
i
l
l
i
m
o
n
s		 Q
2
2
0
0
9		 Q
2
2
0
1
0		 G
h
t
r
o
w		 c
c
T
l
t
o
a
r
e
v
e
n
u
e
(
inc
l.
in
l r
)
te
rn
a
ev
en
ue		 9
5
5		 9
9
4		 4
%		 %
5
E
l
t
e
r
n
a
r
e
e
n
e
x
v
u		 0
9
7		 7
2
2		 2
%		 3
%
N
h
A
i
t
o
r
m
e
r
c
a		 1
9
9		 2
1
0		 5
%
I
i
l
t
t
n
e
r
n
a
o
n
a		 1
0
5		 5
1
2		 0
%		 2
%

cc = constant currency

\$
U
S
i
l
l
i
m
o
n
s		 Q
2
2
0
0
9		 Q
2
2
0
1
0		 G
h
t
r
o
w
N
t
e
r
e
v
e
n
u
e		 2
7
6
4
,		 2
9
4
6
,		 *
7
%
O
i
i
(
E
B
I
T
)
t
p
e
r
a
n
g
n
c
o
m
e		 4
1
8		 5
4
6		 1
1
%
E
B
I
T
i
i
%
m
a
r
g
n
n		 1
1
5		 1
8
5
I
t
t
t
n
e
r
e
s
e
p
e
n
s
e
n
e
x
,		 6
7		 6
8
I
b
f
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 3
4
2		 3
9
7		 1
6
%
I
t
n
c
o
m
e
a
e
p
e
n
s
e
x
x		 1
0
3		 1
2
9
T
t
a
x
r
a
e		 3
0
%		 3
3
%
N
l
l
i
i
t
t
t
o
n
-c
o
n
r
o
n
g
n
e
r
e
s		 1
8		 2
0
N
i
t
e
n
c
o
m
e
C
G
Co
Ga
i
bu
b
le
F
M
A
&
K
A
t
tr
ta
to
a		 2
2
1		 2
4
8		 1
2
%

* 7% growth at constant currency, 6% organic growth

Operating Margin Development

H1 2010 Operating Margin Development

Strong operating cash flow performance

\$
S
U
i
l
l
i
m
o
n
s		 Q
2
2
0
0
9		 Q
2
2
0
1
0		 G
h
t
r
o
w
1)
O
i
h
f
l
t
p
e
r
a
n
g
c
a
s
o
w		 2
8
2		 2
9
4
f r
1
0
%
o
ev
e
nu
e		 4
%
1)
C
i
l
d
i
t
t
a
p
a
e
p
e
n
r
e
s
x
u
t
n
e
,		 (
)
1
3
9		 (
)
1
1
9
F
h
f
l
r
e
e
c
a
s
o
w		 1
4
3		 5
1
7
6
%
f r
o
ev
e
nu
e		 2
3
%
1)
2)
A
i
i
i
t
f
d
i
i
c
q
u
s
o
n
s
t
t
t
n
e
o
v
e
s
u
r
e
s
,		 (
)
4
5		 (
)
6
8
1)
2)
F
h
f
l
f
r
e
e
c
a
s
o
i
i
i
w
t
t
a
e
r
a
c
q
u
s
o
n
s
,		 9
8		 1
0
7

1) A reconciliation to the most directly comparable U.S. GAAP financial measure is provided in the attachment.

2) Does not include a \$133 m cash out for a short-term bank deposit in Q2 2010 and a cash repayment in form of an inter-company loan of \$ 50 m in Q2 2009

Debt/EBITDA ratio ahead of target

* including non-cash charges and in 2007 excluding restructuring costs, in-process R&D and gain from the sale of dialysis clinics. A reconciliation to the most directly comparable U.S. GAAP financial measure is provided in the attachment.

Contacts

Fresenius Medical Care AG & Co. KGaAInvestor RelationsElse-Kröner-Str. 161352 Bad Homburg v.d.H.

Oliver MaierHead of Investor Relations & Corporate Communications Tel.: +49-(0)6172-609-2601 Fax.: +49-(0)6172-609-2301 E-mail: [email protected]

Gerrit JostTel.: +49-(0)6172-609-5216 Fax.: +49-(0)6172-609-2301 E-mail: [email protected]

Terry L. Morris Tel.: +1-800-948-2538Fax.: +1-615-345-5605E-mail: [email protected] Ordinary shares WKN 578 580ISIN DE0005785802SEDOL1 5129074 DE

Q3 2010 Results – Conference Call, November 2, 2010

For recent updates, please have a look at our website. www.fmc-ag.com

CalendarInvestor Relations > Financial Calendar

Annual Report / Quarterly Filings / SEC Filings / Deutsche Börse Filings ... Investor Relations > Publications

Corporate Governance / Sarbanes-Oxley Act / NYSE declaration ... Investor Relations > Corporate Governance

Financing / Analyst Coverage / Consensus estimates / Share data … Investor Relations > Our Shares

Fresenius Medical Care

The World's Leading Renal Therapy Company

Bank of America Merrill Lynch Global Healthcare Conference 2010 September 17, 2010

More from Fresenius Medical Care AG & Co. KGaA

Regulatory Filings 2026
Jan 16
Share Issue/Capital Change 2026
Jan 12
Transaction in Own Shares 2026
Jan 9
Share Issue/Capital Change 2025
Dec 29
AGM Information 2025
Dec 22
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 15
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 12
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 8
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 3
Transaction in Own Shares 2025
Dec 1
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.